Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Director | June 11, 2026 | June 16, 2026 |
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director · Co-Chief Executive Officer · 10% owner | June 12, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PULSE BIOSCIENCES, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 30,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 14,504 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 14,504 · Balance 14,504 F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.
Summit Therapeutics Inc.
Report date June 12, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 573,883,879 |
Reported balance
After 2026-06-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-12 · Purchase · Acquired 3,810,000 · Balance 573,883,879 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee | 25,824,474 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,824,474 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectImmediate family member | 76,680 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 76,680 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee | 10,199,776 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 10,199,776 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 31,000 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 31,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2017 Filed Aug 4, 2017 21:46 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 9,500 | $23.89 | $226,955.00 |
DisclosureSEC source: 0001209191-17-047762 · doc4.xml · nonDerivative · entry 3 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,725 F3 · price: This is the weighted average purchase price of the shares, which ranged from $23.80 to $24.04 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 21:46 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 6,000 | $23.23 | $139,362.00 |
DisclosureSEC source: 0001209191-17-047762 · doc4.xml · nonDerivative · entry 2 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,225 F2 · price: This is the weighted average purchase price of the shares, which ranged from $22.80 to $23.79 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 21:46 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 8,290 | $25.15 | $208,468.63 |
DisclosureSEC source: 0001209191-17-047762 · doc4.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,225 F1 · price: This is the weighted average purchase price of the shares, which ranged from $24.97 to $25.25 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 16, 2017 Filed May 18, 2017 20:08 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $27.14 | $0.00 |
DisclosureSEC source: 0001209191-17-033573 · doc4.xml · derivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-16 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period that will begin on June 1, 2017, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 11, 2017 Filed May 12, 2017 00:03 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 15,000 | $20.84 | $312,540.00 |
DisclosureSEC source: 0001209191-17-031672 · doc4.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,935 F1 · price: This is the weighted average purchase price of the shares, which ranged from $20.66 to $20.945 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 10, 2017 Filed May 12, 2017 00:03 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 5,000 | $21.71 | $108,545.00 |
DisclosureSEC source: 0001209191-17-031672 · doc4.xml · nonDerivative · entry 3 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dependent Minor Disclosed balance after: 85,474 F3 · price: This is the weighted average purchase price of the shares, which ranged from $20.99 to $21.921 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 09, 2017 Filed May 12, 2017 00:03 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 33,760 | $20.16 | $680,500.32 |
DisclosureSEC source: 0001209191-17-031672 · doc4.xml · nonDerivative · entry 2 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dependent Minor Disclosed balance after: 80,474 F2 · price: This is the weighted average purchase price of the shares, which ranged from $19.885 to $20.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 01:48 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 1,040 | $23.78 | $24,731.20 |
DisclosureSEC source: 0001209191-17-021889 · doc4.xml · nonDerivative · entry 4 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dependent Minor Disclosed balance after: 46,714 Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 01:48 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 3,240 | $22.71 | $73,573.92 |
DisclosureSEC source: 0001209191-17-021889 · doc4.xml · nonDerivative · entry 3 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dependent Minor Disclosed balance after: 45,674 F3 · price: This is the weighted average purchase price of the shares, which ranged from $22.53 to $23.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 01:48 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 5,000 | $22.47 | $112,360.00 |
DisclosureSEC source: 0001209191-17-021889 · doc4.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,935 F1 · price: This is the weighted average purchase price of the shares, which ranged from $22.46 to $22.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| March 20, 2017 Filed Mar 28, 2018 19:51 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 1,000 | $22.38 | $22,380.00 |
DisclosureSEC source: 0001209191-18-021891 · doc5.xml · nonDerivative · entry 7 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Immediate Family Member 2 Disclosed balance after: 14,000 Read SEC document |
| March 20, 2017 Filed Mar 28, 2018 19:51 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 2,000 | $22.37 | $44,740.00 |
DisclosureSEC source: 0001209191-18-021891 · doc5.xml · nonDerivative · entry 4 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Immediate Family Member 1 Disclosed balance after: 27,000 Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 01:48 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 8,960 | $24.00 | $215,004.16 |
DisclosureSEC source: 0001209191-17-021889 · doc4.xml · nonDerivative · entry 2 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dependent Minor Disclosed balance after: 42,434 F2 · price: This is the weighted average purchase price of the shares, which ranged from $23.84 to $24.13 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| March 17, 2017 Filed Mar 28, 2018 19:51 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 2,000 | $23.93 | $47,860.00 |
DisclosureSEC source: 0001209191-18-021891 · doc5.xml · nonDerivative · entry 3 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Immediate Family Member 1 Disclosed balance after: 25,000 F2 · price: This is the weighted average purchase price of the shares, which ranged from $23.70 to $24.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| February 15, 2017 Filed Feb 22, 2017 19:48 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 13,000 | $11.97 | $155,649.00 |
DisclosureSEC source: 0001209191-17-013103 · doc4.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Dependent Minor Disclosed balance after: 33,474 F1 · price: This is the weighted average purchase price of the shares, which ranged from $11.95 to $12.05 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| February 15, 2017 Filed Mar 28, 2018 19:51 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 6,200 | $12.15 | $75,342.40 |
DisclosureSEC source: 0001209191-18-021891 · doc5.xml · nonDerivative · entry 6 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Immediate Family Member 2 Disclosed balance after: 13,000 F3 · price: This is the weighted average purchase price of the shares, which ranged from $12.10 to $12.199 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| February 14, 2017 Filed Mar 28, 2018 19:51 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 9,500 | $12.12 | $115,130.50 |
DisclosureSEC source: 0001209191-18-021891 · doc5.xml · nonDerivative · entry 2 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Immediate Family Member 1 Disclosed balance after: 23,000 F1 · price: This is the weighted average purchase price of the shares, which ranged from $12.00 to $12.499 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| February 13, 2017 Filed Mar 28, 2018 19:51 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 1,000 | $10.97 | $10,966.00 |
DisclosureSEC source: 0001209191-18-021891 · doc5.xml · nonDerivative · entry 5 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Immediate Family Member 2 Disclosed balance after: 6,800 Read SEC document |
| February 13, 2017 Filed Mar 28, 2018 19:51 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 2,000 | $11.25 | $22,500.00 |
DisclosureSEC source: 0001209191-18-021891 · doc5.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Immediate Family Member 1 Disclosed balance after: 13,500 Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 18:49 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $7.55 | $0.00 |
DisclosureSEC source: 0001209191-17-009898 · doc4.xml · derivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-02-09 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over three years commencing on the date of grant subject to the Reporting Person's continued service to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.